{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T20:21:14Z","timestamp":1774902074160,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UCB Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1880-4","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:02:41Z","timestamp":1554940961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis\u2014the ANSWER cohort study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1024","authenticated-orcid":false,"given":"Kosuke","family":"Ebina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadao","family":"Jinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,11]]},"reference":[{"issue":"5","key":"1880_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/art.24463","volume":"61","author":"SM Pan Du","year":"2009","unstructured":"Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61(5):560\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1880_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res (Hoboken). 2016;68(4):432\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1880_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22\u201332.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1880_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2013-204128","volume":"74","author":"M Neovius","year":"2015","unstructured":"Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1880_CR5","first-page":"523","volume":"55","author":"A Souto","year":"2016","unstructured":"Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology (Oxford). 2016;55(3):523\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1880_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"1880_CR7","first-page":"ii13","volume":"63","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K, Dewitt EM. Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues. Ann Rheum Dis. 2004;63(Suppl 2):ii13\u2013i7.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1880_CR8","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53(9):1664\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"1880_CR9","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","volume":"54","author":"C Gabay","year":"2015","unstructured":"Gabay C, Riek M, Scherer A, Finckh A. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford). 2015;54(9):1664\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1880_CR10","first-page":"2156","volume":"54","author":"TS Jorgensen","year":"2015","unstructured":"Jorgensen TS, Kristensen LE, Christensen R, Bliddal H, Lorenzen T, Hansen MS, et al. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry. Rheumatology (Oxford). 2015;54(12):2156\u201365.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1880_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1136\/ard.2004.031252","volume":"64","author":"E Hjardem","year":"2005","unstructured":"Hjardem E, Hetland ML, Ostergaard M, Krogh NS, Kvien TK. Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis. 2005;64(8):1220\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1880_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/rheumatology\/keq209","volume":"50","author":"KL Hyrich","year":"2011","unstructured":"Hyrich KL, Watson KD, Lunt M, Symmons DP. Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. Rheumatology (Oxford). 2011;50(1):117\u201323.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1880_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/rheumatology\/keq326","volume":"50","author":"JF Simard","year":"2011","unstructured":"Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, Baecklund E, et al. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford). 2011;50(1):204\u201313.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1880_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194130","volume":"13","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -the ANSWER cohort study. PLoS One. 2018;13(3):e0194130.","journal-title":"PLoS One"},{"issue":"1","key":"1880_CR15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-018-1673-1","volume":"20","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, et al. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther. 2018;20(1):165.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"1880_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1880_CR17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","volume":"71","author":"JD Greenberg","year":"2012","unstructured":"Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71(7):1134\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1880_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"1880_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3109\/03009742.2012.762037","volume":"42","author":"Y Hishitani","year":"2013","unstructured":"Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol. 2013;42(4):253\u20139.","journal-title":"Scand J Rheumatol"},{"issue":"7","key":"1880_CR20","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/ard.2010.140129","volume":"70","author":"HC Leffers","year":"2011","unstructured":"Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011;70(7):1216\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1880_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/art.39399","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare. Arthritis Rheumatol. 2016;68(1):56\u201366.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1880_CR22","first-page":"905","volume":"77","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(6):905\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1880_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000314","volume":"3","author":"M Jani","year":"2017","unstructured":"Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, et al. Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. RMD Open. 2017;3(1):e000314.","journal-title":"RMD Open"},{"issue":"6","key":"1880_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","volume":"72","author":"J Detert","year":"2013","unstructured":"Detert J, Bastian H, Listing J, Weiss A, Wassenberg S, Liebhaber A, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis. 2013;72(6):844\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1880_CR25","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381\u201390.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1880_CR26","doi-asserted-by":"publisher","first-page":"R135","DOI":"10.1186\/ar4315","volume":"15","author":"S Hirata","year":"2013","unstructured":"Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, et al. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther. 2013;15(5):R135.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"1880_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","volume":"72","author":"A Kavanaugh","year":"2013","unstructured":"Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72(1):64\u201371.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1880_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","volume":"74","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, et al. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 2015;74(5):843\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"9870","key":"1880_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918\u201329.","journal-title":"Lancet."},{"issue":"4 Suppl 78","key":"1880_CR30","first-page":"S22","volume":"31","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, Hirata S, Saleem B, Emery P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S22\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"1880_CR31","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/ard.2009.121491","volume":"69","author":"Y Tanaka","year":"2010","unstructured":"Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1880_CR32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/art.23447","volume":"58","author":"H Mitoma","year":"2008","unstructured":"Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58(5):1248\u201357.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1880_CR33","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","volume":"54","author":"H Forsblad-d'Elia","year":"2015","unstructured":"Forsblad-d'Elia H, Bengtsson K, Kristensen LE, Jacobsson LT. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology (Oxford). 2015;54(7):1186\u201393.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1880_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000363","volume":"3","author":"C Takahashi","year":"2017","unstructured":"Takahashi C, Kaneko Y, Okano Y, Taguchi H, Oshima H, Izumi K, et al. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open. 2017;3(1):e000363.","journal-title":"RMD Open."}],"updated-by":[{"DOI":"10.1186\/s13075-019-1897-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000}}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1880-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1880-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1880-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T23:44:24Z","timestamp":1586475864000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1880-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1880"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1880-4","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13075-019-1897-8","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,11]]},"assertion":[{"value":"26 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The representative facility of this registry is Kyoto University, and this observational study was conducted in accordance with the Declaration of Helsinki, and approved by each ethics committee of seven institutes (Kyoto University, Osaka University, Osaka Medical College, Kansai Medical University, Kobe University, Nara Medial University, and Osaka Red Cross Hospital). The details of this study are shown in the homepage of Osaka University Graduate School of Medicine (approval number; 15300), and the board waived the requirement for patients\u2019 informed consent because of the anonymous nature of the data. Written informed consent was obtained from participants in other institutes.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KE received a research grant and\/or speaker fee from Abbvie, Asahi-Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lily, Mitsubishi-Tanabe, Ono Pharmaceutical, Pfizer, Taisho-toyama, and UCB Japan. MH and KM are affiliated with a department that is financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, Ayumi, and UCB Japan) and the city government (Nagahama City). MH received a research grant and\/or speaker fee from Astellas, Mitsubishi-Tanabe, and Bristol-Myers Squibb. TH received a research grant from Astellas, and a speaker fee from Astellas, Chugai, Pfizer, Bristol-Myers Squibb, and Takeda. KM received a speaking fee and\/or consulting fee from Eisai. YM received a research grant and\/or speaker fee from Eli Lily, Chugai, Pfize, Bristol-Myers Squibb, and Mitsubishi-Tanabe. TT is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe, Chugai, Ayumi, Astellas, Eisai, and Takeda). TT received a research grant from Chugai, and a speaker fee from Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Abbvie, Bristol-Myers Squibb, Ayumi, Daiichi Sankyo, Eisai, Takeda, and Asahi-Kasei. MH received a speaker fee from Astellas, Ono Pharmacetical, Eli Lily, Mitsubishi-Tanabe, Pfizer, Ayumi, and Takeda. AK received a research grant and\/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbvie, Bristol-Myers Squibb, Ono Pharmaceutical, Astellas, and Pfizer. HY received a research grant from Chugai, Daiichi Sankyo, and Pfizer. These companies had no role in the study design, decision to publish, or preparation of the manuscript. WY, RH, MK, AO, KN, YS, HA, KY, and SJ declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"91"}}